Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar

Biosimilars are replacing originator compounds due to their similar effectiveness, safety and pharmacokinetics. Our objective was to compare the differences in pharmacokinetics and clinical outcomes between the originator infliximab (Ifx) and the biosimilar CT-P13 in a patient cohort with inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Feito, Ana, Bravo-Gallego, Luz Yadira, Hernández-Breijo, Borja, Diez, Jesús, García-Ramirez, Laura, Jaquotot, Marta, Plasencia-Rodríguez, Chamaida, Nozal, Pilar, Mezcua, Araceli, Martín- Arranz, María Dolores, Pascual-Salcedo, Dora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555902/
https://www.ncbi.nlm.nih.gov/pubmed/33051546
http://dx.doi.org/10.1038/s41598-020-74235-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555902/
https://www.ncbi.nlm.nih.gov/pubmed/33051546
http://dx.doi.org/10.1038/s41598-020-74235-1

Ejemplares similares